Janus kinase inhibitors are of limited use in refractory JIA-associated uveitis: retrospective data from a tertiary uveitis center
Authors' conclusion
Our data show limited effectiveness of JAKi treatment in patients with chronic DMARD-refractory JIAU. The number of patients in whom uveitis quiescence could be observed was low, as was the possibility for reduction of concomitant medication, and the relapse rate was high.
Study context
- Population
- Children with chronic anterior JIA-associated uveitis (JIAU), DMARD-refractory; all had prior MTX, ≥2 biologics ineffective in 18/20
- Participants
- 20 children
- Exposure
- Tofacitinib vs Baricitinib vs Upadacitinib
- Tofacitinibn = 18
- Baricitinibn = 1
- Upadacitinibn = 1
- Outcome
- Uveitis or arthritis inactivity at any time during follow-up
Methodological detailsmonocentric, tertiary uveitis center
- Monocentric
- Tertiary uveitis center
Main finding
As reported in the abstract
Patients with inactive uveitis
8
Subsequent uveitis relapse among them
6
Observational data: associations, not effects.
Further findings
Treatment terminated after ≤ 1 year due to inadequate response of ocular inflammation
- Patients
- 7
New uveitis-related complications · during follow-up
- Patients (eyes)
- 7 (9 eyes)
- Macular edema
- 8 eyes of 7 patients
- Ocular hypertension
- 5 eyes of 3 patients
Reduction of concomitant systemic medication
- Patients
- 3/14
Reduction of topical steroids · during follow-up
- Any reduction (eyes)
- 24/30
- Lower dose at last follow-up vs baseline (eyes)
- 23/30
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →